Celcuity (NASDAQ: CELC) is one of 23 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Celcuity to related companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Valuation & Earnings
This table compares Celcuity and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||427.79|
Insider and Institutional Ownership
15.2% of Celcuity shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Medical laboratories” companies are owned by institutional investors. 43.5% of Celcuity shares are owned by company insiders. Comparatively, 16.6% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Celcuity has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Celcuity’s rivals have a beta of 1.33, suggesting that their average stock price is 33% more volatile than the S&P 500.
This table compares Celcuity and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Celcuity and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity presently has a consensus price target of $35.50, indicating a potential upside of 48.35%. As a group, “Medical laboratories” companies have a potential upside of 2.91%. Given Celcuity’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Celcuity is more favorable than its rivals.
Celcuity beats its rivals on 7 of the 13 factors compared.
Celcuity Company Profile
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.